Brokerages Set Icon Plc (NASDAQ:ICLR) PT at $219.64

Icon Plc (NASDAQ:ICLR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nineteen analysts that are covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $216.6667.

ICLR has been the topic of several analyst reports. Barclays upped their target price on Icon from $155.00 to $180.00 and gave the company an "equal weight" rating in a report on Friday, July 25th. Truist Financial increased their target price on Icon from $187.00 to $234.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Jefferies Financial Group lowered Icon from a "buy" rating to a "hold" rating and lowered their price target for the company from $220.00 to $175.00 in a research report on Tuesday. Citigroup reissued a "neutral" rating and issued a $200.00 price target (down from $225.00) on shares of Icon in a research report on Thursday, August 21st. Finally, Baird R W raised Icon from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 24th.

Icon Stock Performance

Shares of Icon stock traded down $0.11 during trading on Tuesday, reaching $175.00. The company's stock had a trading volume of 1,597,382 shares, compared to its average volume of 967,129. The business's 50-day moving average price is $167.87 and its 200-day moving average price is $157.70. The firm has a market cap of $14.13 billion, a PE ratio of 18.00, a P/E/G ratio of 2.59 and a beta of 1.20. Icon has a 52 week low of $125.10 and a 52 week high of $310.54. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35.

Icon (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, beating analysts' consensus estimates of $3.18 by $0.08. The business had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $1.98 billion. Icon had a return on equity of 10.95% and a net margin of 9.82%.Icon's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.75 earnings per share. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. Equities analysts forecast that Icon will post 13.38 earnings per share for the current year.

Institutional Trading of Icon

A number of large investors have recently modified their holdings of ICLR. Artisan Partners Limited Partnership lifted its position in Icon by 67.4% in the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company's stock worth $1,045,039,000 after buying an additional 2,893,946 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Icon by 21.0% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company's stock valued at $545,730,000 after purchasing an additional 650,379 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Icon by 3.3% during the second quarter. Invesco Ltd. now owns 3,085,993 shares of the medical research company's stock valued at $448,858,000 after acquiring an additional 98,032 shares in the last quarter. Ninety One UK Ltd lifted its holdings in shares of Icon by 2.6% during the second quarter. Ninety One UK Ltd now owns 2,993,652 shares of the medical research company's stock valued at $435,427,000 after purchasing an additional 75,465 shares in the last quarter. Finally, Ruane Cunniff & Goldfarb L.P. lifted its holdings in shares of Icon by 36.2% during the second quarter. Ruane Cunniff & Goldfarb L.P. now owns 1,708,183 shares of the medical research company's stock valued at $248,455,000 after purchasing an additional 453,833 shares in the last quarter. Institutional investors own 95.61% of the company's stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.